Nasdaq:US$18.78 (-0.58) | HKEX:HK$29.90 (+0.00) | AIM:£2.97 (-0.08)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors